Assembly Biosciences (ASMB) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Salim Syed maintained a Buy rating on Assembly Biosciences (ASMBResearch Report) today and set a price target of $14.00. The company’s shares closed last Tuesday at $2.22.

According to, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.0% and a 35.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Unity Biotechnology.

Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $9.17.

See today’s best-performing stocks on TipRanks >>

Based on Assembly Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.09 million. In comparison, last year the company had a GAAP net loss of $27.2 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Read More on ASMB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More